[11/28/11/29 FRONTEO Life Science AI Business Academy] Medical DX has started in earnest Anticipating the pharmaceutical business in the age of AI and big data | FRONTEO, Inc. | Providing business solutions with in-house developed AI

[11/28/11/29 FRONTEO Life Science AI Business Academy] Medical DX starts in earnest Anticipating the pharmaceutical business in the age of AI and big data

2022/11/9

As the promotion of DX accelerates in pharmaceutical companies, hospitals, local governments, academia, etc., the government's "Medical DX Promotion Headquarters" was launched in October 2022.
With the establishment of a nationwide medical information platform and the standardization of electronic medical records, it is expected that the amount of usable data will continue to increase in the future.
More than ever, DX promotion is required.

This time, we have invited Mr. Yoshiyuki Numata, Editor-in-Chief of MIX, to talk about the overall picture and flow of medical DX, focusing on the latest topics.

You can choose any convenient date from the following.

(both have the same content)↓

① [Live streaming] 11/28 (Monday) 18: 15-19: 00:https://lifescience.fronteo.com/webinar20221128

② [Recording distribution] 11/29 (Tue) 12: 15-13: 00:https://lifescience.fronteo.com/webinar20221129

【Webinar Summary】

Theme: Full-scale start of medical DX Anticipating the pharmaceutical business in the age of AI and big data

◆ Date and time: We will deliver the same content twice.Please select any time according to your convenience.

①11/28 (Monday) 18:15-19:00
②11/29 (Tue) 12:15-13:00

◆ Format: Free web seminar (only PC environment that can connect to the Internet is required)

◆ Participation conditions:

Please refrain from applying for those who use free addresses, those who are in the same industry as our company, or those whose affiliation is unknown.When accessing ZOOM on the day of the event, please enter the name and email address you provided when you applied for the ZOOM participation input field.

◆Speakers

Representative Director of Mix Co., Ltd.

Editor-in-chief of Monthly Mix
Yoshiyuki Numata

After graduating from Kitasato University in 1987, joined a foreign pharmaceutical company.He belongs to the sales division and works as a medical representative (MR).Based on this experience, since 1992 he has been a reporter for a daily newspaper for the pharmaceutical industry, covering the Ministry of Health, Labor and Welfare, the pharmaceutical industry, and the medical and medical world.He moved to Elsevier Japan Co., Ltd. in December 2008 after working as a cap, desk and editor. He became editor-in-chief of Monthly Mix. In July 12, the business was transferred from Elsevier Japan to Mix Co., Ltd., and he is currently serving as CEO and editor-in-chief of Mix Co., Ltd.

Share this article

0
Facebook
Twitter

<To the previous article

To the next article>

Share this article

0
Facebook
Twitter

Articles in the same category

[5/31 15th Fraud Countermeasures Study Session] [Must-see for compliance personnel] Mass media response in the event of a crisis

[Online seminar held on 5/9] New framework and practical outlook for European foreign investment regulations - Explanation of the European Commission's new regulation proposal and the regulatory environment of major countries -

[Real seminar held on 4/18] “Crisis management proposed by a competition law/consumer law boutique firm” ~Risk management to avoid a “crisis”~

Exploring patient stratification biomarkers for IgA nephropathy using AI: Overcoming bias with AI

Searching for therapeutic targets for pancreatic cancer - I tried using paper search AI -

Parkinson's disease - Analyzing drug discovery targets using paper search AI

Economic Security Symposium co-hosted by FRONTEO x Moody's Analytics Japan on April 4th

Searching for new targets for sporadic ALS using AI: Become friends with AI

[Webinar held on 3/25] Risk of important information leakage of Japanese companies due to cross-border application of discovery and its response